ORGANIZATION
FPMAJ “Not Opposed” to Company Requirements for Receiving Price Maintenance Premium: Kamoya
Yoshiaki Kamoya, chairman of the Federation of Pharmaceutical Manufacturers’ Associations of Japan’s (FPMAJ) pricing affairs committee, said on June 16 that the FPMAJ “is not opposed” to the proposed revision of company requirements for receiving the so-called price maintenance premium,…
To read the full story
Related Article
ORGANIZATION
- Industry Hails Japan Growth Roadmap, PhRMA Urges Follow-Through
June 25, 2026
- Boehringer’s Hasson Appointed EFPIA Japan Vice Chair
June 22, 2026
- Think Tank Opposes Cap on Social Security Burden Ratio, Urges Pause in Off-Year Price Cuts
June 22, 2026
- Japanese Drug Makers Step Up Use of ASEAN Reliance Reviews
June 18, 2026
- Ease Foreign Price Adjustment Rules for New Drugs to Counter MFN Policy: FPMAJ
June 15, 2026
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…





